CN101597289B - 2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester and preparation method and application thereof - Google Patents
2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester and preparation method and application thereof Download PDFInfo
- Publication number
- CN101597289B CN101597289B CN2008101144033A CN200810114403A CN101597289B CN 101597289 B CN101597289 B CN 101597289B CN 2008101144033 A CN2008101144033 A CN 2008101144033A CN 200810114403 A CN200810114403 A CN 200810114403A CN 101597289 B CN101597289 B CN 101597289B
- Authority
- CN
- China
- Prior art keywords
- residue
- beta
- benzyl ester
- tryptophyl
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 amino-acid benzyl ester Chemical class 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 229940024606 amino acid Drugs 0.000 claims abstract description 29
- 235000001014 amino acid Nutrition 0.000 claims abstract description 26
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 18
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims abstract description 8
- IDGQXGPQOGUGIX-VIFPVBQESA-N O-BENZYL-l-SERINE Chemical group OC(=O)[C@@H](N)COCC1=CC=CC=C1 IDGQXGPQOGUGIX-VIFPVBQESA-N 0.000 claims abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims abstract description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims abstract description 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims abstract description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims abstract description 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims abstract description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
- ARLVFKCLBYUINL-UHFFFAOYSA-N 9h-pyrido[3,4-b]indole-3-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1C=NC(C(=O)O)=C2 ARLVFKCLBYUINL-UHFFFAOYSA-N 0.000 claims description 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 10
- 229960004799 tryptophan Drugs 0.000 claims description 10
- NFVNYBJCJGKVQK-ZDUSSCGKSA-N N-[(Tert-butoxy)carbonyl]-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CNC2=C1 NFVNYBJCJGKVQK-ZDUSSCGKSA-N 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 229960002989 glutamic acid Drugs 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical group OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 206010039491 Sarcoma Diseases 0.000 abstract description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- OJTJKAUNOLVMDX-LBPRGKRZSA-N (2s)-6-amino-2-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 OJTJKAUNOLVMDX-LBPRGKRZSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 41
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 18
- 229950004288 tosilate Drugs 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 8
- 230000006837 decompression Effects 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 229930182817 methionine Natural products 0.000 description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 229960004217 benzyl alcohol Drugs 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 2
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- TYQYRKDGHAPZRF-INIZCTEOSA-N benzyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)OCC1=CC=CC=C1 TYQYRKDGHAPZRF-INIZCTEOSA-N 0.000 description 2
- BVCTWRNVKLXEQC-HNNXBMFYSA-N benzyl (2s)-2-amino-3-(4-hydroxyphenyl)propanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=C(O)C=C1 BVCTWRNVKLXEQC-HNNXBMFYSA-N 0.000 description 2
- ZYSSRDBCZVJBPQ-INIZCTEOSA-N benzyl (2s)-2-amino-3-phenylmethoxypropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)OCC1=CC=CC=C1 ZYSSRDBCZVJBPQ-INIZCTEOSA-N 0.000 description 2
- FPRSPUHXEPWUBZ-HNNXBMFYSA-N benzyl (2s)-2-amino-3-phenylpropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 FPRSPUHXEPWUBZ-HNNXBMFYSA-N 0.000 description 2
- MBRRYUQWSOODEO-LBPRGKRZSA-N benzyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OCC1=CC=CC=C1 MBRRYUQWSOODEO-LBPRGKRZSA-N 0.000 description 2
- YGYLYUIRSJSFJS-QMMMGPOBSA-N benzyl (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OCC1=CC=CC=C1 YGYLYUIRSJSFJS-QMMMGPOBSA-N 0.000 description 2
- IHRYAQVOEVWURS-SCZZXKLOSA-N benzyl (2s,3r)-2-amino-3-hydroxybutanoate Chemical compound C[C@@H](O)[C@H](N)C(=O)OCC1=CC=CC=C1 IHRYAQVOEVWURS-SCZZXKLOSA-N 0.000 description 2
- TZPOCDBWQWIDSX-JQWIXIFHSA-N benzyl (2s,3s)-2-amino-3-methylpentanoate Chemical compound CC[C@H](C)[C@H](N)C(=O)OCC1=CC=CC=C1 TZPOCDBWQWIDSX-JQWIXIFHSA-N 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910000071 diazene Inorganic materials 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101100540419 Danio rerio kdrl gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- COSOUWSZFHWATE-VIFPVBQESA-N benzyl (2s)-2,4-diamino-4-oxobutanoate Chemical compound NC(=O)C[C@H](N)C(=O)OCC1=CC=CC=C1 COSOUWSZFHWATE-VIFPVBQESA-N 0.000 description 1
- AXIQMEOYYYWDKF-LBPRGKRZSA-N benzyl (2s)-2-amino-3-(1h-imidazol-5-yl)propanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CNC=N1 AXIQMEOYYYWDKF-LBPRGKRZSA-N 0.000 description 1
- QQBUEAQIKXPFPP-NSHDSACASA-N benzyl (2s)-5-(diaminomethylideneamino)-2-nitramidopentanoate Chemical compound NC(=N)NCCC[C@H](N[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 QQBUEAQIKXPFPP-NSHDSACASA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention discloses 2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester and a preparation method and the application thereof, belonging to the biological medicine field. The structure formula of the 2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester is shown in the general formula I, wherein AA is selected from valine residue, aspartic acid-Gamma-benzyl ester, glutamine, N<Omega> carbobenzoxy-Lysine, leucine residue, alanine residue, tryptophan residue, O-benzyl serine residue, phenylalanine residue, isoleucine residue, glycin residue, histidine residue, methionine residue, glutamate-Delta-benzyl ester, asparagine residue, proline residue, p-methoxy benzyl cysteine, nitryl arginine residue, threonine residue or tyrosine residue. The antitumor activity of the compound having the general formula I is evaluated by a tumor cell model and a S180 mouse sarcoma model, and the experimental result shows that the compound having the general formula I has excellent antitumor function and can be used as antitumor agent.
Description
Technical field
The present invention relates to amino acid derivative, relate in particular to 2-tryptophyl-beta-tetrahydro carboline-3-formyol amino-acid benzyl ester with anti-tumor activity and preparation method thereof, the present invention also further relates to them as antineoplastic application, belongs to biomedicine field.
Background technology
Malignant tumour is a kind of common disease and frequently-occurring disease of serious threat human health, and the mortality ratio that the mankind cause because of malignant tumour is second of all disease death rates, is only second to cardiovascular and cerebrovascular diseases.The tumor treatment method has operative treatment, radiotherapy and pharmacological agent (chemotherapy).At present, chemotherapy remains the main means of clinical treatment tumour.Seeking antitumor drug is one of focus of new drug research.The contriver recognizes, with after beta-tetrahydro carboline carboxylate and the coupling of L-tryptophane again carboxyl terminal introduce amino acid and may produce antitumor action.According to this conception, the contriver proposes the present invention.
Summary of the invention
One of the object of the invention provides the compound that a class has anti-tumor activity;
Two of the object of the invention provides a kind of above-mentioned method with active compound for anti tumor for preparing.
Above-mentioned purpose of the present invention is achieved through the following technical solutions:
Compound of Formula I with anti-tumor activity:
AA is selected from Xie Ansuan residue, aspartic acid-γ-benzyl ester, glutamine residue, N in the formula
ω-carbobenzoxy-(Cbz) lysine residue, leucine residue, alanine residue, tryptophan residue, O-benzyl serine residue, phenylalanine residue, Isoleucine residue, glycine residue, histidine residues, methionine residue, L-glutamic acid-δ-benzyl ester, asparagine residue, proline residue, to methoxy-benzyl halfcystine, nitro arginine, threonine residues or tyrosine residues.
A kind of method for preparing above-mentioned compound of Formula I, this method comprises:
(1) (at NaOH, (Boc)
2O and dioxane exist down) tryptophan transfer is become the Boc-tryptophane;
(2) (at rare H
2SO
4Under the existence of formaldehyde) tryptophan transfer is become beta-tetrahydro carboline-3-carboxylic acid;
(3) (in the presence of polyphosphoric acid and benzylalcohol heating) changes beta-tetrahydro carboline-3-carboxylic acid into beta-tetrahydro carboline-3-benzyl carboxylate;
(4) (in the presence of tosic acid, benzylalcohol and hexanaphthene) changes amino acid into amino-acid benzyl ester;
(5) (in the presence of DCC and HoBt) is with Boc-tryptophane and beta-tetrahydro carboline-3-benzyl carboxylate condensation prepared 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-benzyl carboxylate;
(6) (use Pd/C catalysis) 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-benzyl carboxylate hydrogenolysis is prepared 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-carboxylic acid;
(7) (in the presence of DCC, HoBt) is with 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-carboxylic acid and amino-acid benzyl ester condensation prepared 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-formyl amino acid formyl amino acid benzyl ester;
(8) (in the presence of HOAc, hydrogenchloride and ethyl acetate) sloughs Boc with 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-formyl amino acid formyl amino acid benzyl ester, promptly.
Wherein, the amino-acid benzyl ester described in the step (4) be selected from the two benzyl esters of Xie Ansuan benzyl ester, aspartic acid, glutamine benzyl ester, (N ω-carbobenzoxy-(Cbz)) Methionin benzyl ester, leucine benzyl ester, alanine benzyl ester, tryptophan benzyl ester, O-benzyl Serine benzyl ester, Isoleucine benzyl ester, phenylalanine benzyl ester, glycine benzyl ester, histamine acid benzyl ester, methionine(Met) benzyl ester, the two benzyl esters of L-glutamic acid, l-asparagine benzyl ester, proline(Pro) benzyl ester, to methoxy-benzyl halfcystine benzyl ester, nitro arginine benzyl ester, tyrosine benzyl ester or threonine benzyl ester.
Another purpose of the present invention provides a kind of medicinal compositions for the treatment of tumour, this medicinal compositions is gone up effective dose by treatment compound of Formula I of the present invention is with pharmaceutically acceptable excipient or assist and add agent and form, the compound of Formula I of the present invention that is about to significant quantity is with after pharmaceutically acceptable carrier or thinner cooperate, and by the formulation method of this area routine it is prepared into any one appropriate drug composition.Usually said composition is suitable for oral administration and drug administration by injection, also is fit to other medication.Said composition can be liquid preparation forms such as tablet, capsule, pulvis, granule, lozenge, suppository, or oral liquid.According to different medications, pharmaceutical composition of the present invention can contain 0.1%-99% weight, the The compounds of this invention of preferred 10-60% weight.
The present invention is at tumor models and mouse S
180Estimated the anti-tumor activity of compound of Formula I (2a-t) on the sarcoma model, experimental result shows that general formula 1 compound of the present invention has outstanding anti-tumor activity, can be used as antineoplastic agent and uses.
Description of drawings
The structural formula of Fig. 1 compound of Formula I of the present invention.
The synthetic route chart of Fig. 2 compound of Formula I of the present invention; The middle AA of 2a-t is selected from Xie Ansuan, aspartic acid-γ-benzyl ester, glutamine, N
ω-carbobenzoxy-(Cbz) Methionin, leucine, L-Ala, tryptophane, O-benzyl Serine, phenylalanine, Isoleucine, glycine, Histidine, methionine(Met), L-glutamic acid-δ-benzyl ester, l-asparagine, proline(Pro), to methoxy-benzyl halfcystine, nitro arginine, Threonine or tyrosine residues.
Embodiment
In order further to set forth the present invention, provide a series of embodiment below.These embodiment are illustrative fully, and they only are used for the present invention is specifically described, and not should be understood to limitation of the present invention.
Embodiment 1 preparation Boc-L-tryptophane
Under the ice bath 4.1g (2mol) L-tryptophane is dissolved in the 10mlNaOH aqueous solution (2N), in this solution, adds 4.9g (2.2mmol) (Boc)
2O and 5ml 1, the solution of 4-dioxane, compound of reaction stir and constantly reduce pressure and take out the CO that generates in the dereaction process
2Need after 48 hours TLC to detect reaction approximately and finish, decompression removes 1, the 4-dioxane, and residual nothing is used earlier saturated KHSO
4The aqueous solution is transferred pH 2, uses ethyl acetate extraction then three times, and the ethyl acetate layer of merging is given a baby a bath on the third day after its birth with the saturated NaCl aqueous solution and time then used anhydrous Na SO
4Dried overnight is filtered, and filters colorless solid that also concentrating under reduced pressure obtains with ethyl acetate-sherwood oil recrystallization.Yield: 85%.
Embodiment 2 preparation L-amino-acid benzyl fat
20mmolL-amino acid and 30ml phenylcarbinol stirred in the 100ml round-bottomed flask make dissolving.Add 3.78g (22mol) tosic acid then, 90 ℃ of stirrings.Take the water that generates in the reaction process out of with the hexanaphthene azeotropic.TLC detects the basic disappearance of raw material point after 24 hours, stops heating, cooling, and ice bath stirs a large amount of ether of adding down, separates out the amino-acid benzyl ester tosilate.Productive rate is between 86%-96%.Logical according to this method has been synthesized Xie Ansuan benzyl ester tosilate, the two benzyl ester tosilate of aspartic acid, N ω-carbobenzoxy-(Cbz) Methionin benzyl ester tosilate, leucine benzyl ester tosilate, the alanine benzyl ester tosilate, the tryptophan benzyl ester tosilate, O-benzyl Serine benzyl ester tosilate, phenylalanine benzyl ester tosilate, Isoleucine benzyl ester tosilate, the glycine benzyl ester tosilate, Histidine benzyl ester tosilate, methionine(Met) benzyl ester tosilate, the two benzyl ester tosilate of L-glutamic acid, proline(Pro) benzyl ester tosilate, the tosilate of the amino acid whose benzyl esters of L-such as threonine benzyl ester tosilate and tyrosine benzyl ester tosilate.
Embodiment 3 preparation beta-tetrahydro carboline-3-carboxylic acids
Slowly add the 0.2ml vitriol oil in the 500ml round-bottomed flask that contains 400ml water and shake up.Dilution heat of sulfuric acid that obtains and 5.0g (24.5mmol) L-tryptophane is stirred to the L-tryptophane and dissolves fully.Add 10ml formaldehyde (35%) in the solution that obtains, separate out a large amount of solids behind the stirring 10min, the TLC plate detects the L-tryptophane and disappears, and stops to stir.In reaction solution, slowly splash into 8ml ammoniacal liquor, transfer pH7.Reaction mixture sat 6h, decompression leaches the precipitation of generation, water flushing 5 times, dry 4.9g (95%) target compound that gets of filter Pie is light yellow solid.ESI(m/z)217[M+H]
+.
Embodiment 4 preparation beta-tetrahydro carboline-3-benzyl carboxylates
Get 2g polyphosphoric acid heated and stirred and make it to be dissolved in 20ml benzylalcohol (Heating temperature is not higher than 50 ℃), treat to dissolve fully the back and add 1g beta-tetrahydro carboline-3-carboxylic acid, be warming up to 80 ℃ of stirrings, reaction solution turns brown gradually by yellow-green colour, and TLC detects the disappearance of raw material point after 12 hours.Reaction mixture cooling back adds the 50ml ether and powerful stirring of 70ml water spent the night, and has a large amount of yellow solids to separate out.Filter, the yellow blocks of solid that obtains is washed repeatedly with ether and water and is obtained Powdered light yellow carboline carboxylate benzyl ester phosphoric acid salt 1.3g.This phosphoric acid salt is suspended in the mixed solution of ethyl acetate and water, it is transparent that ice bath drips down triethylamine solution no insoluble particle and reaction solution to the reaction solution.After continuing to stir 12h, tell ethyl acetate layer also with 5% sodium bicarbonate aqueous solution washing 6 times, saturated sodium-chloride water solution washing 3 times, the ethyl acetate layer of telling concentrates with anhydrous sodium sulphate solid drying, filtration, filtrate decompression, the residue recrystallization gets 0.9g (67%) title compound, is the ivory buff powder.ESI(m/e)307[M+H]
+。
Embodiment 5 preparation Boc-tryptophyl-beta-tetrahydro carboline-3-benzyl carboxylates (1A)
3.6g (11.8mmol) Boc-L-tryptophane is dissolved in 35ml anhydrous tetrahydro furan (THF), adds the solution of 1.4g (14.2mmol) N-hydroxybenzotriazole (HOBt) and 2.1g (14.2mmol) dicyclohexyl carbonyl diimine (DCC) and 15ml anhydrous tetrahydro furan (THF) under the ice bath inward.The reaction mixture ice bath stirred 20 minutes, got corresponding active ester solution.Add 2.3g (9.5mmol) beta-tetrahydro carboline-3-benzyl carboxylate and 6ml anhydrous tetrahydro furan (THF) in this solution and transfer the solution of pH=9 with N-methylmorpholine.The mixing solutions room temperature reaction that obtains 24 hours.TLC (developping agent CHCl
3: MeOH=10: 1) show that beta-tetrahydro carboline-3-benzyl carboxylate disappears.Stopped reaction, filtering dicyclohexylurea (DCU) (DCU), filtrate decompression is concentrated into dried.Residue acetic acid ethyl dissolution, ethyl acetate solution are used saturated NaHCO respectively
3The aqueous solution, 5%KHSO
4The aqueous solution, the saturated NaCl aqueous solution is washed 5 times.The ethyl acetate solution anhydrous Na of telling
2SO
4Dried overnight.Filtering Na
2SO
4, filtrate decompression concentrates, and obtains 4.98g (86%) title compound, is colorless solid.Mp 115-117 ℃; ESI (m/e) 550[M+H]
+[α]
D 20=24.30 (c 1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.97 (s, 1H), 10.86 (d, J=15Hz, 1H), 7.57 (t, J=10Hz, 1H), 7.48 (d, J=10Hz, 1H), 7.39 (m, 4H), 7.20 (m, 4H), 6.65 (d, J=5Hz, 1H), 5.05 (s, 2H), 4.31 (s, 2H), 3.47 (s, 2H), 2.98 (d, J=5Hz, 2H), 1.34 (s, 3H).
13C-NMR (DMSO-d
6, 75MHz) δ=206.91,170.82,155.86,136.55,136.16,129.68,128.69,127.79,127.55,126.65,119.19,111.49,110.19,78.66,66.64,55.20,33.82,31.13,28.58; IR:3356.14,3307.92,2974.23,1735.93,1708.93,1678.71,1527.62,1452.40,1420.54,1363.67,1309.67,1244.09,1168.86,734.88.
Embodiment 6 preparation Boc-tryptophyl-beta-tetrahydro carboline-3-carboxylic acids (1B)
Earlier 1.5g (2.52mmol) Boc-tryptophyl-beta-tetrahydro carboline-3-benzyl carboxylate is dissolved in 20ml ethanol, add 300mgPd/C (20%) again, stir the air in the discharge reaction flask that reduces pressure down, feed hydrogen exchange, after replacing 3 times repeatedly, logical hydrogen stirring at room 24 hours, TLC (developping agent CHCl
3: MeOH=10: 1+1 drips Glacial acetic acid) show that Boc-tryptophyl-beta-tetrahydro carboline-3-benzyl carboxylate disappears.Stopped reaction, filtering Pd/C, filter residue washes three times with dehydrated alcohol, and filtrate decompression concentrates, and gets 1.1g (80%) title compound.IR?3396.64,2976.16,2850.79,1705.07,1643.35,1642.06,1510.26,1429.90,1454.33,1392.61,1367.33,1247.94,1234.44,1166.93,742.59。
Method is led in the preparation of embodiment 7Boc-tryptophyl-beta-tetrahydro carboline-3-formyl amino acid formyl amino acid benzyl ester
1.2g (2.4mmol) Boc-tryptophyl-beta-tetrahydro carboline-3-carboxylic acid is dissolved in 15ml anhydrous tetrahydro furan (THF), adds the solution of 600mg (2.5mmol) N-hydroxybenzotriazole (HOBt), 800mg (2.5mmol) dicyclohexyl carbonyl diimine (DCC) and 10ml anhydrous tetrahydro furan (THF) under the ice bath inward.The reaction mixture ice bath stirred 20 minutes, got corresponding active ester solution.Add the N-methylmorpholine elder generation of 2.4mmol amino-acid benzyl ester and 2ml and 6ml anhydrous tetrahydro furan (THF) in this solution and with the solution of NMM accent pH9.The miscible fluid room temperature reaction that obtains spends the night.TLC (developping agent CHCl
3: MeOH=10: 1) show amino acid benzyl ester disappears.Stopped reaction, filtering dicyclohexylurea (DCU) (DCU), filtrate decompression is concentrated into dried.Residue acetic acid ethyl dissolution, ethyl acetate solution are used saturated NaHCO respectively
3The aqueous solution, 5%KHSO
4The aqueous solution, the saturated NaCl aqueous solution is washed 5 times.The ethyl acetate solution anhydrous Na of telling
2SO
4Dried overnight.Filtering Na
2SO
4, filtrate decompression concentrates, and residue is through purification by silica gel column chromatography.
The data of embodiment 8Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-Xie Ansuan benzyl ester (1a)
1.17g(62.42%)。Mp 114-115 ℃; ESI (m/e) 364[M+H]
+[α]
D 20=-114.20 (c 1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.87 (d, J=10Hz, 1H), 8.33 (t, J=5Hz, 1H), 7.635 (d, J=5Hz, 1H), 7.51 (d, J=10Hz, 1H), 7.41 (m, 4H), 7.21 (m, 4H), 4.95 (s, 1H), 4.33 (m, 4H), 4.18 (m, 2H), 4.03 (t, 1H), 3.305 (d, J=5Hz, 1H), 3.14 (m, 2H), 1.38 (s, 3H), 0.83 (s, 3H).
13C-NMR (DMSO-d
6, 75MHz) δ=171.60,170.17,155.80,136.57,129.86,128.89,127.86,127.62,121.11,118.83,111.51,110.20,78.52,66.00,56.31,55.35,30.90,30.50,28.59,18.23; IR 3402.43,3307.92, and 2966.52,1735.93,1680.00,1643.35,1498.69,1454.33,1390.68,1367.53,1366.67,1307.74,1234.44,1163.08,740.67.
The data of the two benzyl esters (1b) of embodiment 9Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-aspartic acid
1.06g (63.8%) .Mp 102-104 ℃; ESI (m/e) 364[M+H]
+[α]
D 20=7.36 (c 1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.90 (s, 1H), 10.87 (s, 1H), 8.65 (d, J=5Hz, 1H), 8.485 (d, J=5Hz, 1H), 7.65 (d, J=10Hz, 1H), 7.515 (d, J=10Hz, 1H), 7.37 (m, 5H), 7.18 (m, 4H), 5.74 (d, J=10Hz, 2H), 4.98 (m, 2H), 4.12 (s, 1H), 3.36 (s, 1H), 3.14 (m, 2H), 1.36 (s, 4H).
13C-NMR (DMSO-d
6, 75MHz) δ=173.11,171.10,170.08,156.32,136.72,136.62,136.09,130.10,129.18,128.05,127.63,126.83,121.11,119.04,111.36,110.72,109.30,79.28,66.70,55.29,52.31,49.50,36.04,28.57,23.40; IR 3388.93,3307.92, and 2954.95,2922.16,1746.65,1683.86,1641.42,1489.05,1456.26,1373.32,1338.60,1282.66,1247.94,1234.44,1163.08,740.67.
The data of embodiment 10Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-glutamine benzyl ester (1c)
0.87g(73.8%)。Mp 154.5-157.0 ℃; ESI (m/e) 721[M+H]
+[α]
D 20=39.23 (c 1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.84 (dd, J=15Hz, J=10Hz, 1H), 8.33 (s, 1H), 7.63 (m, 5H), 7.31 (m, 4H), 5.62 (q, J=5Hz, J=5Hz, 2H), 5.10 (q, J=15Hz, J=15Hz, 1H), 4.25 (d, J=15Hz, 2H), 3.15 (m, 2H), 2.26 (q, J=5Hz, J=5Hz, 2H), 2.10 (s, 2H), 1.33 (t, J=10Hz, 1H);
13C-NMR (DMSO-d
6, 75MHz) δ=174.48,173.33,172.42,171.63,155.63,136.58,130.34,130.24,128.33,127.81,126.85,124.23,121.15,120.68,111.80,110.77,78.59,65.37,55.33,53.25,51.48,39.42,31.13,27.36; IR 3388.93,3329.14, and 2974.23,1687.71,1641.42,1622.13,1489.05,1456.26,1388.75,1367.33,1336.67,1263.37,1163.08,740.67.
The data 1.05g (81.2%) of embodiment 11Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-(N ω-carbobenzoxy-(Cbz)) Methionin benzyl ester (1d).Mp 101-103 ℃; ESI (m/e) 833[M+H]
+[α]
D 20=33.56 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.88 (d, J=15Hz, 1H), 8.45 (d, J=5Hz, 1H), 8.36 (d, J=10Hz, 1H), 7.64 (d, J=10Hz, 1H), 7.40 (m, 4H), 7.19 (m, 4H), 7.06 (m, 3H), 5.735 (d, J=5Hz, 2H), 4.96 (m, 2H), 4.215 (d, J=5Hz, 2H), 3.085 (d, J=5Hz, 1H), 2.94 (m, 3H), 1.38 (s, 3H), 1.28 (s, 2H), 0.91 (m, 2H);
13C-NMR (DMSO-d
6, 75MHz) δ=172.90,172.00,170.01,156.50,136.47,136.31,130.19,129.71,128.05,127.59,119.08,111.37,109.25,79.27,66.24,65.59,55.24,53.15,52.58,50.28,38.91,30.92,30.43,28.58,21.93; IR 3390.86,3288.63, and 3057.17,2972.31,2953.02,1739.79,1678.07,14894.83,1452.40,1336.67,1305.81,1365.60,1236.37,1165.00,740.67.
The data of embodiment 12Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-leucine benzyl ester (1e)
1.37g; (79.5%); Mp:113-115 ℃; ESI (m/e) 707[M+H]
+[α]
D 20=38.27 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.89 (d, J=15Hz, 1H), 8.45 (d, J=10Hz, 1H), 7.61 (dd, J=10Hz, J=5Hz, 1H), 7.34 (m, 5H), 7.20 (m, 4H), 7.08 (m, 1H), 5.70 (s, 2H), 5.14 (dd, J=10Hz, J=7.5Hz, 1H), 4.98 (m, 2H), 2.9 (m, 2H), 1.52 (m, 2H), 1.40 (s, 3H), 0.880 (d, J=5Hz, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=169.96,156.42,136.63,136.48,136.13,130.15,129.63,127.84,127.56,121.53,121.12,119.09,111.48,111.34,110.68,109.19,79.27,66.25,52.36,50.92,41.88,38.94,28.56,23.77,23.17,21.13; IR 3390.86,3311.78, and 2958.80,1741.72,1685.79,1378.07,1529.55,1498.69,1454.33,1336.67,1305.81,1246.02,1234.44,1165.00,740.67.
The data of embodiment 13Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-alanine benzyl ester (1f)
1.00g (82.3%); Mp 115-117 ℃; ESI (m/e) 664[M+H]
+[α]
D 20=20.17 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.90 (d, J=15Hz, 1H), 8.195 (d, J=5Hz, 1H), 7.54 (t, J=7.5Hz, 1H), 7.41 (m, 4H), 7.16 (m, 4H), 6.84 (dd, J=10Hz, J=5Hz, 1H), 5.665 (d, J=5Hz, 1H), 5.43 (s, 2H), 5.08 (m, 2H), 4.23 (t, J=7.5Hz, 2H), 3.96 (m, 2H), 1.41 (s, 3H), 1.38 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=172.64,170.61,136.56,136.10,130.24,129.66,128.61,127.52,126.61,121.65,119.15,118.49,111.60,110.10,109.56,78.66,66.66,66.54,55.33,51.42,28.67,23.18,18.71,18.61; IR 3388.93,3296.35, and 3057.17,2976.16,2931.80,1739.79,1678.07,1527.62,1496.76,1456.26,1390.68,1365.60,1338.60,1305.81,1236.37,1197.79,1161.15,740.67.
The data of embodiment 14Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-tryptophan benzyl ester (1g)
1.22g (78.7%); Mp 129-130 ℃; ESI (m/e) 801[M+H]
+[α]
D 20=0.80 ° (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.87 (d, J=10Hz, 1H), 8.78 (d, J=10Hz, 1H), 8.495 (d, J=5Hz, 1H), 8.015 (d, J=5Hz, 1H), 7.51 (m, 4H), 7.25 (m, 4H), 7.03 (m, 4H), 6.37 (s, 1H), 5.765 (d, J=5Hz, 2H), 5.595 (d, J=5Hz, 2H), 4.50 (t, J=10Hz, 1H), 4.375 (q, J=5Hz, J=5Hz, 1H), 3.00 (q, J=5Hz, J=5Hz, 2H), 1.40 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=173.09,171.93,169.89,156.49,136.59,136.24,129.56,128.11,127.36,126.77,121.32,118.96,111.45,110.72,109.85,79.33,66.29,54.56,53.90,33.83,28.26,28.58,21.16; IR 3365.78,3305.99, and 3032.10,2974.23,2927.94,1735.93,1678.07,1642.06,1498.69,1438.90,1365.60,1338.60,1232.51,1161.15,740.67.
The data of embodiment 15Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-O-benzyl Serine benzyl ester (1h)
1.08g (82.0%); Mp:111-117 ℃; ESI (m/e) 758[M+H]
+[α]
D 20=39.10 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.69 (s, 1H), 10.65 (s, 1H), 8.90 (q, J=5Hz, J=5Hz, 1H), 7.73 (d, J=10Hz, 1H), 7.61 (t, J=5Hz, 1H), 7.25 (m, 5H), 7.09 (m, 4H), 6.84 (d, J=5Hz, 1H), 5.34 (s, 1H), 5.29 (t, 1H), 5.10 (d, J=5Hz, 2H), 4.73 (q, J=5Hz, 2H), 3.54 (t, J=7.5Hz, 2H), 1.38 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=173.24,171.78,170.11,156.08,136.57,136.58,130.07,128.79,127.81,127.68,126.87,121.12,118.96,111.37,110.66,109.42,79.11,72.71,69.31,54.91,53.02,39.09,28.59,23.98; IR 3410.15,3292.49, and 2974.23,2927.94,1743.65,1678.07,1469.76,1442.75,1390.68,1365.60,1336.67,1236.37,1163.08,740.67.
The data of embodiment 16Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-Isoleucine benzyl ester (1i)
1.26g (71.2%); Mp 120-122 ℃; ESI (m/e) 706[M+H]
+[α]
D 20=24.8 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.92 (s, 1H), 10.85 (d, J=5Hz, 1H), 8.29 (s, 1H), 7.62 (d, J=10Hz, 1H), 7.40 (t, J=10Hz, 1H), 7.37 (t, J=5Hz, 1H), 7.32 (m, 4H), 7.22 (m, 4H), 7.135 (d, J=5Hz, 1H), 6.99 (s, 1H), 5.765 (d, J=5Hz, 2H), 5.59 (d, J=10Hz, 2H), 4.87 (t, J=5Hz, 2H), 4.21 (t, J=5Hz, 1H), 3.26 (d, J=10Hz, 1H), 2.99 (m, 1H), 1.37 (s, 3H), 1.28 (m, 2H), 1.155 (d, J=5Hz, 2H), 0.74 (t, J=5Hz, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=172.98,171.60,170.17,156.14,136.56,136.56,136.20,129.98,128.80,127.80,121.11,119.01,118.88,111.35,109.34,79.06,78.58,66.24,54.95,36.84,28.58,28.52,25.31,22.66,15.80,11.16; IR 3309.85,2962.66, and 2927.94,1737.86,1698.64,1639.49,1523.76,1498.69,1454.33,1365.60,1336.67,1307.74,1244.09,1234.44,1165.00,740.67.
The data of embodiment 17Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-phenylalanine benzyl ester (1j)
0.99g (70.3%); Mp:124-126 ℃; ESI (m/e) 740[M+H]
+[α]
D 20=14.6 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.87 (s, 1H), 10.86 (d, J=5Hz, 1H), 8.56 (d, J=5Hz, 1H), 8.40 (d, J=10Hz, 1H), 7.64 (t, J=5Hz, 1H), 7.30 (m, 5H), 7.21 (m, 4H), 6.90 (m, 4H), 5.07 (s, 2H), 5.03 (d, J=5Hz, 2H), 4.98 (q, J=5Hz, 1H), 4.41 (t, J=5Hz, 1H), 4.35 (d, J=5Hz, 1H), 3.12 (d, J=5Hz, 2H), 2.10 (s, 2H), 1.41 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=171.56,169.78,156.55,137.59,136.40,136.23,129.53,129.38,128.34,127.83,127.53,124.15,121.08,119.11,111.33,110.76,109.08,66.47,54.44,52.35,38.36,36.39,28.67,28.56,21.25; IR 3402.43,3304.06, and 2974.23,2931.80,17393.39,1678.07,1649.14,1496.76,1444.68,1365.60,1336.67,1305.81,1234.44,1166.93,742.59.
The data of embodiment 18Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-glycine benzyl ester (1k)
1.09g (76.5%); Mp 139-143 ℃; ESI (m/e) 650[M+H]
+[α]
D 20=19.9 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.89 (d, J=5Hz, 1H), 10.87 (s, 1H), 8.48 (dd, J=10Hz, J=5Hz, 1H), 8.41 (s, 1H), 7.465 (d, J=5Hz, 1H), 7.40 (d, J=10Hz, 1H), 7.28 (m, 5H), 7.12 (m, 4H), 7.025 (d, J=15Hz, 1H), 5.735 (d, J=5Hz, 2H), 4.945 (d, J=5Hz, 1H), 4.835 (d, J=5Hz, 2H), 4.31 (s, 1H), 4.28 (s, 1H), 3.04 (dd, J=10Hz, J=5Hz, 2H), 1.40 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=171.33,169.88,155.80,136.69,136.24,130.07,128.84,129.34,127.82,126.85,124.19,121.37,118.90,118.00,111.80,111.50,109.65,66.31,52.31,28.61,22.28; IR 3394.72,3296.35, and 2974.94,2927.94,1743.65,1639.49,1498.69,1452.40,1367.53,1336.67,1278.81,1234.44,1165.00,738.74.
The data of embodiment 19Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-histamine acid benzyl ester (1l)
0.56g (53.2%); Mp 138-140 ℃; ESI (m/e) 730[M+H]
+[α]
D 20=19.9 (c=1.0, methyl alcohol);
1HNMR (CDCl
3) δ/ppm=13.4 (s, 1H), 10.23 (s, 1H), 10.01 (s, 1H), 8.02 (s, 1H), 7.45 (s, 1H), 7.27 (d, J=5Hz, 1H), 7.19 (m, 5H), 7.18 (m, 4H), 6.88 (s, 1H), 6.86 (d, J=7.5Hz, 1H), 6.65 (d, J=5Hz, 1H), 5.87 (s, 2H), 5.59 (d, J=7.5Hz, 2H), 4.61 (s, 2H), 4.81 (t, J=5Hz, 1H), 3.06 (d, J=5Hz, 2H), 3.00 (d, J=10Hz, 2H), 2.51 (m, 1H), 1.99 (s, 2H), 1.39 (s, 9H);
13CNMR (CDCl
3) δ/ppm=172.30,169.88,157.21,136.64,131.24,130.22,128.78,127.74,121.64,121.15,118.91,118.70,111.36,110.51,104.89,78.72,66.55,55.17,52.43,34.94,31.10,29.73,28.57,27.40,24.89,22.80; IR3331.07,3070.68,2926.01,2848.86,2115.91,1627.92,1507.06,1448.54,1435.04,1363.67,1346.30,1309.67,1271.09,1230.58,1186.22,1157.29,891.11,738.74.
The data of embodiment 20Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-methionine(Met) benzyl ester (1m)
1.06g (55.4%); Mp 97-99 ℃; ESI-MS (m/e) 746[M+H]
+[α]
D 20=33.5 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.895 (d, J=15Hz, 1H), 7.57 (d, J=10Hz, 1H), 7.30 (m, 5H), 7.12 (m, 5H), 6.705 (d, J=5Hz, 1H), 5.595 (d, J=5Hz, 2H), 4.66 (t, J=7.5Hz, 2H), 3.605 (d, J=5Hz, 2H), 2.955 (q, J=10Hz, 2H), 2.38 (s, 3H), 1.50 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=170.87,155.46,136.48,128.87,128.24,127.86,121.36,118.82,110.20,66.24,50.83,39.44,33.82,28.56,24.39; IR 3400.50,3304.06, and 3055.24,2970.38,2918.30,1747.51,1685.96,1498.69,1456.26,1367.53,1338.60,1234.44,1163.38,740.67.
The data of the two benzyl esters (1n) of embodiment 21Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-L-glutamic acid
0.96g (63.2%); Mp 99-101 ℃; ESI-MS (m/e) 834[M+H]
+[α]
D 20=8.2 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.87 (d, J=10Hz, 1H), 8.505 (d, J=5Hz, 1H), 8.445 (d, J=5Hz, 1H), 7.635 (d, J=5Hz, 1H), 7.54 (t, J=5Hz, 1H), 7.40 (m, 4H), 7.18 (m, 4H), 5.725 (d, J=5Hz, 2H), 5.13 (m, 1H), 5.06 (s, 2H), 3.31 (m, 2H), 1.31 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=172.89,171.53,170.16,156.40,136.56,129.73,128.84,127.58,121.31,118.85,117.89,111.34,79.34,66.40,52.41,30.51,28.55,26.46,21.93; IR 3311.78,3273.20, and 2951090,2924.09,1735.93,1678.07,1624.06,1498.69,1454.33,1390.68,0367.53,1338.60,1350.81,1236.37,1163.08,740.67.
The data of embodiment 22Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-l-asparagine benzyl ester (1o)
1.17g (56.2%); Mp 141-143 ℃; ESI (m/e) 726[M+H]
+[α]
D 20=7.2 (c=1.0, methyl alcohol)
1H-NMR (DMSO-d
6, 500MHz) δ=10.88 (s, 1H), 10.84 (s, 1H), 8.44 (d, J=5Hz, 1H), 7.66 (d, J=5Hz, 1H), 7.43 (d, J=5Hz, 1H), 7.23 (m, 4H), 7.04 (m, 4H), 5.74 (d, J=10Hz, 2H), 4.72 (t, J=5Hz, 1H), 4.68 (t, J=7.5Hz, 1H), 4.61 (s, 2H), 4.59 (t, J=5Hz, 1H), 3.35 (d, J=10Hz, 2H), 3.12 (m, 2H), 2.59 (d, J=5Hz, 2H), 1.39 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=173.07,171.64,170.89,156.05,136.34,130.07,127.97,127.27,121.44,121.10,118.93,110.74,109.45,79.65,66.37,55.08,52.54,49.72,38.85,36.97,31.12,28.58; IR 3348.42,3331.07, and 2974.23,2927.94,1739.79,1678.07,1496.76,1456.26,1390.68,1367.53,1336.67,1309.67,1161.15,740.67.
The data of embodiment 23Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-proline(Pro) benzyl ester (1p)
0.99g (80.3%); Mp 133-135 ℃; ESI (m/e) 690[M+H]
+[α]
D 20=-118.8 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.88, (d, J=10Hz, 1H), 7.645 (d, J=5Hz, 1H), 7.64 (m, 1H), 7.28 (m, 5H), 7.22 (m, 4H), 5.78 (d, J=10Hz, 2H), 4.84 (m, 2H), 4.38 (t, J=10Hz, 2H), 3.48 (m, 2H), 3.07 (m, 2H), 1.38 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=172.28,171.97,155.71,136.58,136.45,130.10,128.97,127.73,127.63,126.92,121.06,118.86,111.32,110.43,104.71,78.70,66.28,59.17,52.76,47.04,31.12,28.80,28.59,22.89,22.02; IR 3390.86,3315.63, and 3057.17,2974.23,1743.65,1639.49,1496.67,1454.82,1365.60,1336.67,1271.09,1238.30,1166.93,740.67.
Embodiment 24Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-to the data of methoxy-benzyl halfcystine benzyl ester (1q)
1.32g (78.6%); Mp 101-103 ℃; ESI (m/e) 816[M+H]
+[α]
D 20=-14.3 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.89 (d, J=15Hz, 1H), 8.495 (d, J=5Hz, 1H), 7.650 (d, J=5Hz, 1H), 7.500 (m, 5H), 7.25 (m, 5H), 7.150 (m, 4H), 5.805 (d, J=5Hz, 2H), 4.83 (s, 1H), 3.70 (s, 2H), 3.63 (s, 3H), 3.375 (d, J=5Hz, 2H), 1.340 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=172.79,170.54,156.45,138.22,136.45,136.16,129.79,129.24,128.82,127.58,127.29,121.14,119.11,111.37,110.77,109.19,79.34,78.58,66.69,55.37,52.44,35.59,32.18,28.16,21.58; IR 3402.43,3307.92, and 2966.52,2931.80,1741.72,1680.00,1643.35,1498.69,1454.33,1390.68,1367.53,1336.67,1307.74,1234.44,1163.08,740.67.
The data of embodiment 25Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-nitro arginine benzyl ester (1r)
1.01g (79.0%); Mp 103-105 ℃; ESI (m/e) 795[M+H]
+[α]
D 20=18.6 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.89 (s, 1H), 10.86 (s, 1H), 8.49 (d, J=10Hz, 1H), 8.33 (s, 1H), 7.64 (d, J=10Hz, 1H), 7.60 (d, J=10Hz, 1H), 7.485 (d, J=5Hz, 1H), 7.33 (m, 4H), 7.17 (m, 4H), 5.73 (d, J=10Hz, 2H), 5.15 (t, J=7.5Hz, 2H), 4.91 (m, 2H), 4.18 (t, J=7.5Hz, 2H), 3.58 (t, J=5Hz, 2H), 2.10 (s, 1H), 1.67 (m, 1H), 1.38 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=171.98,170.10,159.81,156.34,136.61,136.32,130.20,136.24,130.20,129.78,128.89,127.84,127.60,121.14,119.06,111.37,110.68,109.27,79.65,78.60,66.58,52.86,31.15,28.26,22.05; IR 3311.78,3273.20, and 2974.23,2931.80,1793.79,1685.79,1624.06,1529.55,1454.33,1440.83,1390.68,1365.60,1338.60,1255.66,1163.08,740.67.
The data of embodiment 26Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-threonine benzyl ester (1s)
1.38g (71.0%); Mp 125-127 ℃; ESI (m/e) 694[M+H]
+[α]
D 20=9.7 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.87 (t, J=7.5Hz, 1H), 10.77 (s, 1H), 8.18 (d, J=10Hz, 1H), 7.98 (d, J=10Hz, 1H), 7.31 (m, 5H), 7.08 (m, 5H), 5.88 (d, J=15Hz, 2H), 5.05 (m, 2H), 3.11 (m, 2H), 3.01 (m, 2H), 2.10 (s, 1H), 1.37 (s, 3H), 1.31 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=171.87,136.74,136.54,129.53,128.10,127.79,126.94,126.85,124.26,121.08,118.88,118.47,111.49,111.33,110.59,109.60,66.81,66.65,58.62,58.30,54.55,31.75,31.13,20.61.IR 3373.50,3313.71,2958.80,2924.09,2852.72,1743.65,1685.79,1624.06,1498.69,1442.75,1390.68,1367.53,1334.74,1307.74,1234.44,1165.00,740.67.
The data of embodiment 27Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-tyrosine benzyl ester (1t)
1.20g (43.2%); Mp 145-146 ℃; ESI (m/e) 778[M+H]
+[α]
D 20=29.9 (c=1.0, methyl alcohol);
1H-NMR (DMSO-d
6, 500MHz) δ=10.86 (d, J=10Hz, 1H), 8.525 (d, J=5Hz, 1H), 7.78 (d, J=10Hz, 1H), 7.50 (m, 5H), 7.25 (m, 5H), 5.605 (d, J=5Hz, 1H), 4.94 (m, 2H), 3.38 (m, 2H), 3.09 (d, J=10Hz, 2H), 1.43 (s, 3H);
13C-NMR (DMSO-d
6, 75MHz) δ=171.47,169.92,156.60,136.59,136.07,130.35,129.68,128.36,128.03,127.83,127.58,126.75,121.34,119.52,119.52,118.75,115.60,111.85,110.18,79.37,66.35,54.85,35.76,31.14,28.59,24.93; IR 3392.79,3311.78, and 2974.23,2927.94,1739.79,1643.35,1502.55,1440.83,1367.53,1338.60,1242.16,1234.44,1166.93,738.74.
Method is led in the preparation of embodiment 282-tryptophyl-beta-tetrahydro carboline-3-formyl radical-amino-acid benzyl ester hydrochloride
3.18mmol Boc-tryptophyl-beta-tetrahydro carboline-3-formyl radical-amino-acid benzyl ester is placed the 50mL eggplant-shape bottle and uses the 2mL acetic acid ethyl dissolution.Ice bath slowly splashes into 2mL 4N hydrogenchloride/EtOAc down in the solution that obtains.0 ℃ of stirring of reaction mixture is evaporated to dried after 3 hours, residue extracts (10ml * 4) repeatedly with ether earlier, uses methyl alcohol-ether recrystallization then, obtains title compound.
The data of embodiment 292-tryptophyl-beta-tetrahydro carboline-3-formyl radical-Xie Ansuan benzyl ester hydrochloride (2a)
0.092g(80%);ESI(m/e)590[M-H]
-.
1HNMR(CDCl
3):δ/ppm=10.99(s,1H),10.92(s,1H),8.11(s,1H),7.40(m,1H),7.30(m,5H),7.21(m,4H),7.01(d,J=10Hz,1H),6.97(s,1H),5.25(d,J=10Hz,1H),4.93(t,J=7.5Hz,1H),4.85(d,J=10Hz,1H),4.54(s,2H),3.93(m,1H),3.06(d,J=10Hz,2H),2.80(d,J=10Hz,2H),2.08(s,2H),1.05(d,J=7.5Hz,6H);
13CNMR(CDCl
3)δ/ppm=167.99,136.55,136.20,129.00,128.82,127.63,125.32,121.74,119.16,118.94,112.08,107.26,66.34,65.37,57.71,52.74,33.80,24.90,18.58,17.92,15.63。
The data of the two benzyl ester hydrochlorides (2b) of embodiment 302-tryptophyl-beta-tetrahydro carboline-3-formyl radical-aspartic acid
0.107g(83%);ESI(m/e)696[M-H]
-.
1HNMR(CDCl
3)δ/ppm=10.42(s,1H),8.23(s,1H),7.27(d,J=2Hz,1H),7.21(m,10H),7.14(m,4H),6.76(t,J=10Hz,1H),5.78(d,J=7.5Hz,1H),5.21(s,2H),5.18(s,2H),5.02(d,J=3Hz,1H),4.96(t,J=5Hz,1H),4.34(s,2H),3.40(t,J=7.5Hz,1H),3.04(d,J=10Hz,1H),2.94(d,J=7.5Hz,2H),2.87(d,J=7.5Hz,1H),1.99(s,2H);
13CNMR(CDCl
3)δ/ppm=170.51,169.50,136.51,136.20,129.77,128.77,127.53,126.74,121.62,119.04,106.85,104.21,66.71,66.28,54.97,51.016,49.31,36.11,17.63,22.81。
The data of embodiment 312-tryptophyl-beta-tetrahydro carboline-3-formyl radical-glutamine benzyl ester hydrochloride (2c)
0.083g(81%);ESI(m/e)602[M-H]
-.
1HNMR(CDCl
3):δ/ppm=10.06(s,1H),8.15(s,1H),7.23(m,5H),7.19(m,4H),7.00(m,1H),6.95(d,J=7.5Hz,1H),6.82(s,1H),6.32(s,2H),5.28(d,J=5Hz,2H),4.93(t,J=7.5Hz,1H),4.88(s,1H),4.50(s,2H),4.33(t,J=7.5Hz,1H),3.94(m,1H),3.06(d,2H),2.12(m,2H),1.92(s,2H);
13CNMR(CDCl
3)δ/ppm=172.36,171.55,170.50,136.45,129.77,127.60,127.35,123.01,121.55,121.20,120.00,119.06,111.80,111.45,106.78,56.48,52.27,41.62,27.23,23.86,21.51。
The data of embodiment 322-tryptophyl-beta-tetrahydro carboline-3-formyl radical-(N ω-carbobenzoxy-(Cbz)) Methionin benzyl ester hydrochloride (2d)
0.078g(82.0%);ESI-MS(m/e)709[M-H]
-.1HNMR(CDCl3)δ/ppm=10.91(s,1H),10.87(s,1H),8.24(s,lH),8.09(s,1H),7.29(m,10H),7.27(m,1H),7.19(m,4H),7.17(d,J=7.5Hz,1H),6.75(t,J=5Hz,1H),5.79(d,J=7.5Hz,2H),5.24(s,2H),4.92(t,J=5Hz,1H),4.42(s,2H),4.39(t,J=7.5Hz,1H),4.03(m,1H),3.05(q,J=7.5Hz,J=7.5Hz,2H),2.09(s,2H),1.92(m,2H),1.64(m,2H),1.33(m,2H);13CNMR(CDCl3)δ/ppm=171.99,170.03,169.76,156.55,137.74,136.75,130.01,129.76,128.20,127.57,121.56,119.20,111.58,106.78,66.27,65.36,52.56,50.87,42.26,30.94,29.44,23.16,15.62。
The data of embodiment 332-tryptophyl-beta-tetrahydro carboline-3-formyl radical-leucine benzyl ester hydrochloride (2e)
0.103g(90%);ESI-MS(m/e)604[M-H]
-.
1HNMR(CDCl
3)δ/ppm=11.02(s,1H),10.87(s,1H),8.23(s,1H),7.72(d,J=7.5Hz,1H),7.31(m,1H),7.27(m,5H),7.20(m,4H),7.02(d,J=5Hz,1H),6.97(t,J=10Hz,1H),5.68(d,J=5Hz,1H),5.24(s,2H),4.98(t,J=7.5Hz,1H),4.58(d,J=5Hz,2H),4.40(s,2H),4.18(m,1H),3.40(m,1H),2.51(s,2H),1.10(t,J=5Hz,1H),7.32(d,J=6Hz,6H);
13CNMR(CDCl
3)δ/ppm=172.22,171.07,170.02,169.77,129.93,129.70,128.19,127.53,121.63,119.18,111.57,106.76,106.39,66.27,65.36,54.38,50.99,42.24,24.21,23.14,21.74。
The data of embodiment 342-tryptophyl-beta-tetrahydro carboline-3-formyl radical-alanine benzyl ester hydrochloride (2f)
0.089g(91.0%);ESI(m/e)562[M-H]
-.
1HNMR(CDCl
3)δ/ppm=11.02(s,1H),10.87(s,1H),8.23(s,1H),7.72(d,J=7.5Hz,1H),7.31(m,1H),7.27(m,5H),7.20(m,4H),7.02(d,J=5Hz,1H),6.97(t,J=5Hz,1H),5.68(d,J=5Hz,1H),5.24(s,2H),4.98(t,J=7.5z,1H),4.58(d,J=5Hz,2H),4.40(s,2H),4.18(m,1H),3.40(m,1H),2.51(s,2H),1.10(t,J=5Hz,1H),7.32(d,J=6Hz,6H);
13CNMR(CDCl
3)δ/ppm=172.22,171.07,170.02,169.77,129.93,129.70,128.19,127.53,121.63,119.18,111.57,106.76,106.39,66.27,65.36,54.38,50.99,42.24,24.21,23.14,21.74。
The data of embodiment 352-tryptophyl-beta-tetrahydro carboline-3-formyl radical-tryptophan benzyl ester hydrochloride (2g)
0.107g(80%);ESI(m/e)677[M-H]
-.
1HNMR(CDCl
3)δ/ppm=10.50(s,1H),8.14(s,1H),10.06(s,1H),7.26(d,J=2.5Hz,1H),7.21(m,5H),7.18(m,8H),6.97(m,1H),6.92(t,J=7.5Hz,1H),6.75(t,J=5Hz,1H),5.40(s,2H),4.92(d,J=3.0Hz,1H),4.80(d,J=10.25Hz,1H),4.45(s,2H),4.37(m,1H),3.18(d,J=7.5Hz,1H),3.07(d,J=8.3Hz,4H),2.00(s,1H);
13CNMR(CDCl
3)δ/ppm=172.03,170.06,136.62,128.73,128.30,126.72,125.18,124.27,119.03,117.99,111.93,66.34,65.37,53.99,51.61,47.98,33.80,27.93,25.81,24.91,15.63。
The data 0.088g (86.0%) of embodiment 362-tryptophyl-beta-tetrahydro carboline-3-formyl radical-O-benzyl Serine benzyl ester hydrochloride (2h); ESI (m/e) 654[M-H]
-.
1HNMR (CDCl
3) δ/ppm=10.55 (s, 1H), 8.20 (s, 1H), 7.26 (t, J=7.5Hz, 1H), 7.20 (m, 10H), 7.10 (m, 4H), 6.96 (d, J=7.5Hz, 1H), 6.71 (d, J=7.5Hz, 1H), 5.53 (d, J=7.5Hz, 2H), 4.98 (t, J=5Hz, 1H), 4.86 (t, J=5Hz, 1H), 4.67 (s, 2H), 3.90 (m, 1H), 3.88 (d, J=10Hz, 2H), 3.21 (d, J=7.5Hz, 4H), 1.99 (s, 2H);
13CNMR (CDCl
3) δ/ppm=171.28,170.18,169.71,138.26,137.77,136.58,130.09,129.74,128.71,128.13,127.97,121.54,119.01,117.90,111.96,106.79,72.77,69.54,66.53,54.27,52.99,26.40,23.75.
The data of embodiment 372-tryptophyl-beta-tetrahydro carboline-3-formyl radical-Isoleucine benzyl ester hydrochloride (2i)
0.111g(93%);ESI(m/e)604[M-H]
-.1HNMR(CDCl3)δ/ppm=10.92(s,1H),8.24(s,1H),7.27(m,1H),7.22(m,5H),7.20(m,1H),7.14(m,4H),6.93(s,2H),5.83(d,J=10Hz,1H),5.24(s,2H),4.91(t,J=10Hz,3H),4.88(t,J=5Hz,1H),4.54(s,2H),4.15(t,J=7.5Hz,1H),3.14(m,1H),3.06(d,J=10Hz,2H),1.99(s,2H),1.06(d,J=5Hz,3H),0.88(t,J=5Hz,3H);13CNMR(CDCl3)δ/ppm=171.46,169.96,167.98,136.75,130.28,129.81,128.77,127.61,126.79,121.50,119.15,111.59,106.68,104.28,66.31,57.12,53.88,36.91,33.80,27.43,25.41,24.89,15.89,11.62。
The data of embodiment 382-tryptophyl-beta-tetrahydro carboline-3-formyl radical-phenylalanine benzyl ester hydrochloride (2j)
0.120g(91%);ESI(m/e)638[M-H]
-.1HNMR(CDCl
3)δ/ppm=10.82(s,1H),10.76(s,1H),8.17(s,1H),7.25(m,5H),7.22(m,1H),7.18(m,4H),7.15(m,1H),6.98(m,1H),6.93(d,J=5Hz,1H),6.76(t,J=7.5Hz,1H),5.75(d,J=7.5Hz,1H),4.94(t,J=5Hz,1H),4.80(t,J=7.5Hz,1H),4.45(s,2H),3.80(t,J=??Hz,1H),3.29(d,J=7.5Hz,2H),3.07(d,J=7.8Hz,1H),2.91(d,J=7.3Hz,2H),2.50(s,2H);
13CNMR(CDCl
3)δ/ppm=171.42,170.86,169.88,137.71,136.12,129.89,129.05,128.78,127.53,126.93,126.72,121.67,119.20,119.05,111.61,111.43,106.87,66.46,63.65,54.14,51.44,36.73,36.53,23.15。
The data 0.078g (96%) of embodiment 392-tryptophyl-beta-tetrahydro carboline-3-formyl radical-glycine benzyl hydrochloride (3k); ESI (m/e) 547[M-H]
-.1HNMR (CDCl3) δ/ppm=9.08 (s, 1H), 8.93 (s, 1H), 8.19 (s, 1H), 7.53 (m, 1H), 7.44 (m, 1H), 7.32 (m, 5H), 7.22 (m, 4H), 6.98 (d, J=5Hz, 1H), 6.97 (d, J=5Hz, 1H), 5.89 (d, J=5Hz, 2H), 5.47 (s, 2H), 5.03 (t, J=5Hz, 1H), 5.00 (s, 2H), 4.27 (m, 1H), 3.09 (m, 1H), 3.01 (d, J=7.5Hz, 2H), 1.99 (s, 2H);
13CNMR (CDCl
3) δ/ppm=169.97,166.32,165.89,136.61,128.67,127.58,127.07,124.49,121.47,118.95,118.05,111.97,109.51,66.72,65.36,49.50,42.28,41.77,28.79,15.62.
The data of embodiment 402-tryptophyl-beta-tetrahydro carboline-3-formyl radical-Histidine benzyl ester hydrochloride (2l)
0.087g(81%);ESI(m/e)628[M-H]
-.1HNMR(CDCl
3)δ/ppm=10.52(s,1H),9.55(s,1H),8.06(s,1H),7.44(d,J=10Hz,1H),7.25(s,5H),7.17(m,4H),7.07(m,1H),6.18(t,J=5Hz,1H),5.85(d,J=5Hz,2H),5.77(d,J=7.5Hz,1H),4.87(t,J=7.5Hz,1H),4.83(t,J=5Hz,1H),4.55(s,2H),4.00(t,J=7.5Hz,1H),3.12(d,J=10Hz,2H),3.06(m,2H),1.21(s,2H);
13CNMR(CDCl
3)δ/ppm=170.31,169.97,157.20,136.64,129.69,128.23,127.57,121.53,11904,118.31,111.57,106.52,63.63,53.20,48.00,33.77,25.80,22.95。
The data of embodiment 412-tryptophyl-beta-tetrahydro carboline-3-formyl radical-methionine(Met) benzyl ester hydrochloride (2m)
0.096g(85%);ESI(m/e)618[M-H]
-.
1HNMR(CDCl
3)δ/ppm=10.99(s,1H),10.88(s,1H),8.26(s,1H),7.27(m,1H),7.22(m,5H),7.17(m,4H),6.84(s,1H),6.82(d,J=7.5Hz,1H),5.54(s,2H),4.55(d,J=5Hz,1H),4.53(s,2H),3.69(m,1H),3.42(t,J=7.5Hz,2H),3.12(d,J=5Hz,2H),2.79(d,J=5Hz,2H),2.43(t,J=10Hz,2H),2.41(m,2H),2.09(s,3H),2.01(s,2H);
13CNMR(CDCl
3)δ/ppm=167.97,136.53,128.87,128.22,127.62,125.68,121.71,119.13,118.48,112.07,107.26,65.83,65.47,49.65,45.93,42.35,27.64。
The data of the two benzyl ester hydrochlorides (2n) of embodiment 422-tryptophyl-beta-tetrahydro carboline-3-formyl radical-L-glutamic acid
0.078g(86%);ESI(m/e)710[M-H]
-.
1HNMR(CDCl
3)δ/ppm=11.01(s,1H),10.85(s,1H),8.23(s,1H),7.36(m,10H),7.26(m,1H),7.18(m,4H),6.97(d,J=7.5Hz,1H),5.78(d,J=7.5Hz,1H),5.40(s,2H),4.99(t,J=10Hz,1H),4.82(t,J=5Hz,1H),4.39(s,2H),4.34(m,1H),3.18(d,J=5Hz,2H),2.35(q,J=5Hz,J=5Hz,2H),2.24(t,J=7.5Hz,2H),1.99(s,2H);
13CNMR(CDCl
3)δ/ppm=172.55,172.40,171.39,136.84,136.59,136.20,129.96,128.87,128.21,127.58,121.65,119.20,111.59,111.42,106.85,66.45,65.98,52.29,33.80,27.61,26.37,24.13,23.25。
The data of embodiment 432-tryptophyl-beta-tetrahydro carboline-3-formyl radical-l-asparagine benzyl ester hydrochloride (2o)
0.089g(87%);ESI(m/e)605[M-H]
-.
1HNMR(CDCl
3)δ/ppm=10.48(s,1H),10.46(s,1H),8.15(s,1H),7.27(m,1H),7.23(m,5H),7.19(m,4H),6.86(d,J=10Hz,1H),6.73(d,J=7.5Hz,1H),5.79(d,J=7.5Hz,2H),4.92(t,J=7.5Hz,1H),10.64(t,J=5Hz,1H),4.50(s,2H),4.40(t,J=7.5Hz,1H),3.04(d,J=10Hz,2H),2.65(d,J=7.5Hz,2H),1.99(s,2H);
13CNMR(CDCl
3)δ/ppm=171.24,169.72,136.59,128.76,128.01,127.57,126.88,121.57,119.01,117.93,111.88,106.41,89.25,66.39,54.65,49.61,36.85,29.36,26.45,21.80。
The data of embodiment 442-tryptophyl-beta-tetrahydro carboline-3-formyl radical-proline benzyl ester hydrochloride (2p)
0.122g(89%);ESI(m/e)588[M-H]
-.
1HNMR(CDCl
3)δ/ppm=10.34(s,1H),8.16(s,1H),7.27(m,1H),7.24(m,5H),7.17(m,4H),7.06(m,1H),6.92(d,J=7.5Hz,1H),6.82(t,J=10Hz,1H),5.72(d,J=7.5Hz,2H),4.89(t,J=10Hz,1H),4.45(s,1H),4.31(t,J=7.5Hz,2H),4.01(m,1H),3.80(t,J=7.5Hz,2H),3.09(d,J=7.5Hz,2H),3.06(d,J=5Hz,2H),2.30(m,2H),2.00(s,2H);
13CNMR(CDCl
3)δ/ppm=173.40,169.07,136.86,136.50,128.97,128.00,127.58,125.61,121.68,121.37,119.21,119.06,111.57,111.38,106.74,67.76,59.15,51.39,49.30,47.21,28.92,23.46,22.30。
Embodiment 452-tryptophyl-beta-tetrahydro carboline-3-formyl radical-to the data 0.121g (83%) of methoxy-benzyl halfcystine benzyl ester hydrochloride (2q); ESI (m/e) 668[M-H]
-.
1HNMR (CDCl
3) δ/ppm=10.88 (s, 1H), 8.24 (s, 1H), 7.22 (m, 5H), 7.19 (m, 4H), 7.04 (m, 1H), 7.00 (d, J=7.5Hz, 1H), 5.30 (s, 2H), 4.93 (m, 2H), 4.41 (s, 2H), 3.77 (m, 1H), 3.72 (s, 2H), 3.37 (s, 3H), 3.32 (t, J=10Hz, 2H), 2.82 (t, J=7.5Hz, 4H), 1.92 (s, 2H);
13CNMR (CDCl
3) δ/ppm=170.59,170.09,169.75,136.70,136.16,129.44,129.22,128.15,127.54,127.24,121.69,121.64,119.05,112.05,111.60,111.45,66.71,65.35,52.32,35.77,35.53,32.10,23.99.
The data of embodiment 462-tryptophyl-beta-tetrahydro carboline-3-formyl radical-nitro arginine benzyl ester hydrochloride (2r)
0.086g(85%);ESI(m/e)692[M-H]
-.
1HNMR(CDCl
3)δ/ppm=10.01(s,1H),9.10(s,1H),8.08(s,1H),8.03(s,1H),7.31(m,1H),7.29(m,5H),7.22(m,4H),7.16(m,1H),7.00(d,J=2.5Hz,1H),6.97(d,J=7.5Hz,1H),6.95(d,J=7.5Hz,1H),5.24(s,2H),4.95(t,J=7.5Hz,1H),4.50(s,2H),4.03(m,1H),3.07(d,J=10Hz,1H),3.03(t,J=10Hz,2H),2.50(t,J=5Hz,2H),2.09(s,2H),1.99(s,1H),1.92(s,1H),1.73(m,2H),1.57(m,2H);
13CNMR(CDCl
3)δ/ppm=172.36,171.95,159.82,136.79,136.27,128.88,128.24,127.60,126.87,124.90,121.55,119.05,113.42,111.88,66.47,65.33,63.65,52.48,50.97,28.41,25.46,21.51。
The data of embodiment 472-tryptophyl-beta-tetrahydro carboline-3-formyl radical-threonine benzyl ester hydrochloride (2s)
0.101g(87%);ESI(m/e)592[M-H]
-.
1HNMR(CDCl
3)δ/ppm=10.78(s,1H),10.55(s,1H),8.32(s,1H),7.27(m,1H),7.23(m,5H),7.12(m,4H),6.97(m,1H),6.82(d,J=5Hz,1H),6.78(s,1H),6.71(d,J=10Hz,1H),5.53(s,2H),4.93(m,1H),4.69(t,J=5Hz,1H),4.52(t,J=5Hz,1H),4.46(s,2H),2.51(d,J=5Hz,1H),1.91(s,2H),1.23(d,J=5Hz,3H);
13CNMR(CDCl
3)δ/ppm=171.58,170.23,169.44,136.32,130.17,129.59,128.80,127.68,127.58,126.52,121.50,119.21,111.55,68.13,67.37,65.34,58.90,51.56,42.24,27.41,20.76,20.09,16.63。
The data of embodiment 482-tryptophyl-beta-tetrahydro carboline-3-formyl radical-tyrosine benzyl ester hydrochloride (2t)
0.098g(83%);ESI-MS(m/e)654[M-H]
-.
1HNMR(CDCl
3)δ/ppm=10.76(s,1H),8.14(s,1H),7.27(d,J=5Hz,1H),7.20(m,5H),7.10(m,4H),6.97(d,J=7.5Hz,1H),6.87(d,J=7.5Hz,1H),6.79(s,1H),6.76(d,J=7.5Hz,2H),6.55(s,2H),5.07(s,1H),4.94(t,J=7.5Hz,1H),4.82(t,J=5Hz,1H),4.03(t,1H),3.31(d,J=7.5Hz,2H),3.25(d,J=Hz,2H),2.96(t,J=7.5Hz,2H),1.99(s,2H);
13CNMR(CDCl
3)δ/ppm=169.49,136.46,136.16,130.49,130.43,128.74,127.69,127.55,121.66,121.25,119.55,111.44,110.18,106.59,66.39,63.69,54.13,52.80,35.83,33.80,23.14,15.62。
The evaluation of experimental example 1 The compounds of this invention (2a-t) anti-tumour cell proliferative activity
1) given the test agent
The compound compound (2a-t) that embodiment of the invention 29-48 is prepared; Be mixed with desired concn with the PBS that contains 1%DMSO.
2) human cancer cell strain
S180 cell (ascitogenous sarcoma cell), H22 cell (Murine Ascitic Hepatoma Cells strain)
3) key instrument
Microplate reader: 450, Biorad company
High-pressure sterilizing pot: 400Ep-Z, Bruckmanning company
Cell incubator: INC153, memmer company
Refrigerated centrifuge: SPD111V, Thermo company
96 porocyte culture plates: Costar company
Quartzy automatic dual pure water distiller: 1,810 one B, Jiangsu high honour instrument Manufacturing Co., Ltd
4) main agents
MTT: four tetrazolium bromides (3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl-tetrazolium bromide) (Flka), is dissolved among the PBS, and concentration is 5mg/ml, filtration sterilization, and 4 ℃ keep in Dark Place.
PBS: contain NaCl 8.2g in every liter of solution, KCl 0.20g, Na
2HPO
4.H
2O1.56g, KH
2PO
40.2g pH 7.4
RPMI-1640 substratum: Gibco company
DMEM substratum: Gibco company
Mccy ' the s 5A medium+L-Glutamine substratum of improvement: Gibco company
Foetal calf serum: Hyclone company
Penicillin: Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Shiyao Group
Streptomycin sulphate: Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Shiyao Group
DMSO:Hyclone company.
All the other agents useful for same are commercially available analytical pure.
5) experimental technique of The compounds of this invention 2a-t anti-tumour cell proliferative evaluation
Respectively that growth conditions is good, be in the HL-60 cell of logarithmic phase with 5 * 10
4The density of individual/mL is inoculated in 96 orifice plates, every hole 100 μ l, by default concentration gradient add to be measured, through the sample of sterilising treatment, control group adds the solvent of isopyknic sample dissolution.Continue to cultivate after 48 hours, it is the MTT solution of 5mg/ml that every hole adds 25 μ l concentration, continue to place 37 ℃ to hatch four hours, the careful sucking-off supernatant liquor of centrifugal 5min (2500rpm), every hole adds the DMSO dissolve purple residue (first a ceremonial jade-ladle, used in libation) of 100 μ l, all dissolvings of about 15min precipitation of vibrating are measured O.D. (absorption value), wavelength 570nm on the 570nm microplate reader.
Calculate sample under each sample concentration to the inhibiting rate of tumour cell according to formula " relative survival rate=(D pastille-D blank)/(D contrast-D blank) * 100% ".
Experiment repeats 3 times, with inhibiting rate drug level is mapped, and obtains IC by graphing method
50(half effective inhibition concentration) value.
6) experimental result
Experimental result sees Table 1.
Table 12a-t anti-tumour cell proliferative activity (IC
50± SD μ M)
Compound | S180 | H22 |
2a | 7.50±3.68 | >10 |
2b | 5.85±2.16 | 5.64±1.23 |
2c | >10 | >10 |
2d | >10 | >10 |
2e | 6.46±2.36 | 6.37±1.63 |
2f | >10 | >10 |
2g | 5.93±1.66 | 4.92±2.01 |
2h | 6.81±2.68 | 9.87±3.66 |
2i | 6.67±2.31 | 6.32±1.68 |
2j | 5.37±2.64 | 5.40±2.31 |
2k | 9.98±5.32 | 9.95±1.98 |
2l | 7.75±3.65 | >10 |
2m | >10 | >10 |
2n | 5.68±1.32 | 5.72±2.31 |
2o | >10 | >10 |
2p | >10 | >10 |
2q | 7.65±2.31 | >10 |
2r | >10 | >10 |
2s | >10 | 9.86±3.55 |
2t | >10 | >10 |
Arc | 5.46±3.98 | 8.66±2.44 |
1A | 7.96±3.96 | 7.06±4.33 |
The anti-tumor activity experiment of experimental example 2 The compounds of this invention 2a-t
1) experiment material
The compound compound (2a-t) that test-compound: embodiment of the invention 29-48 is prepared;
Positive reference substance is a cytosine arabinoside
Laboratory animal: SCI mouse (KM cleans level), male, body weight 20 ± 2g (x ± s); Provide available from experimentation on animals center, Department Of Medicine, Peking University.One group of per 12 mouse, each one group of blank and positive control.
Knurl source: mouse S
180Sarcoma is provided by experimentation on animals center, Department Of Medicine, Peking University, goes down to posterity voluntarily and keeps.
Solvent: physiological saline, 0.5%CMC-Na solution.
2) dosage setting
Test-compound 2a-t and cytosine arabinoside are made as 8.9 μ mol/kg, all adopt the abdominal cavity single-dose.
3) medicine preparation
Test-compound 2a-t indissoluble in water adds the wetting hydrotropy of a spot of tween 80 during experiment, add 0.5%CMC-Na solution to required concentration gradually and get final product.Cytosine arabinoside is water-soluble, adopts physiological saline solution.
4) dosage and dosage regimen
Test-compound 2a-t is all with the abdominal cavity single-dose.By corresponding dosage once a day, the 0.2ml/ mouse, successive administration 7 days, administration is 7 times altogether.
Negative control is with isopyknic corresponding solution, all with intraperitoneal administration.By corresponding dosage once a day, the 0.2ml/ mouse, successive administration 7 days, administration is 7 times altogether.
Cytosine arabinoside is by the dosage of 8.9 μ mol/kg, intraperitoneal administration.Once a day, the 0.2ml/ mouse, successive administration 7 days, administration is 7 times altogether.
5) animal model
Adopt anti-tumor in vivo armpit subcutaneous vaccination model: under aseptic condition, extract inoculation and get the vigorous S of growth after 7 days
180Ascitic tumor knurl liquid, be diluted to the liquid thorough mixing of (1: 2) with physiological saline, the tumour cell suspension is dyeed with freshly prepared 0.2% trypan blue, count by the white blood cell count(WBC) method behind the mixing, dye blue person and be dead cell, tinter is not a viable cell, is calculated as follows cell concn and cell survival rate.
Viable count/4 * 10 in the big grid in cell concn=4
4* extension rate=cell count/ml
Cell survival rate=viable count/(viable count+dead cell number) * 100%
Survival rate is prepared into 1 * 10 greater than 90% knurl liquid with the homogenate method
7The cell suspension of individual/ml in corresponding host's armpit subcutaneous vaccination 0.2ml/ mouse, is made the solid tumor animal model.
6) detect index and method
7) neurotoxicity is observed in the body
Observe autonomic activities, the mental status, hair, breathing, the diet of the reaction mouse of each treated animal of administration every day, the ight soil proterties.
8) mensuration of solid tumor tumour inhibiting rate and body weight gain
Each is organized successive administration and took off cervical vertebra after 7 days in the 8th day and put to death mouse, takes by weighing body weight (execution body weight), with the fixing right armpit tumor location of mouse of tweezers, cuts off skin then, the exposure tumour, and blunt separation is weighed, and is calculated as follows tumour inhibiting rate.
The average knurl of the average knurl weight-administration of tumour inhibiting rate %=[(negative control group group is heavy)/the average knurl of negative control group is heavy] * 100%
Body weight gain (g)=execution body weight-original body weight-knurl is heavy
9) mensuration of liver weight, spleen index and thymus index
Adopt the mouse after weighting method is promptly peeled off tumour, dissect again and take out brain, liver, kidney and spleen, take by weighing brain heavy (g), liver heavy (g), kidney heavy (g), spleen heavy (mg), and be calculated as follows spleen index.
Spleen index (mg/kg)=spleen weight/execution body weight
10) statistical method
This experimental data statistics all adopts t check and variance analysis, with (x ± SD) expression.
11) experimental result
Test-compound 2a-t is to lotus S
180The anti-tumor in vivo activity experiment result of sarcoma lists table 2 in.Dosage is 8.9 μ mol/kg, and after 7 days, average tumor weight is 1.69 ± 0.61g to 049 ± 0.12g through continuous intraperitoneal administration; The average tumor weight of negative control group is 1.76 ± 0.54g, there are 10 compounds to have remarkable antitumor effect, compound compound 2a wherein, e, i, l, m, anti-tumor activity and the cytosine arabinoside of r (the heavy scope of knurl is 0.49 ± 0.12g to 0.63 ± 0.20g, compares p<0.05 with the physiological saline group) are suitable.
Table 2 test-compound 2a-t is to lotus S
180The influence of mouse tumor weight
a
A) Arc (cytosine arabinoside) and 2a-t dosage are 8.9 μ mol/kg, the NS=solvent, and n=12, average knurl heavily is expressed as x ± SD g; B) compare p<0.01 with NS, compare p>0.05 with cytosine arabinoside; C) compare p<0.01 with NS, compare p<0.05 with cytosine arabinoside.
Claims (4)
1. the compound of Formula I that has anti-tumor activity:
AA is selected from Xie Ansuan residue, glutamine residue, N in the formula
ω-carbobenzoxy-(Cbz) lysine residue, leucine residue, alanine residue, tryptophan residue, O-benzyl serine residue, phenylalanine residue, Isoleucine residue, glycine residue, histidine residues, methionine residue, asparagine residue, proline residue, to methoxy-benzyl halfcystine, nitro arginine residues, threonine residues or tyrosine residues; And
The two benzyl esters of compound 2-tryptophyl-beta-tetrahydro carboline-3-formyl radical-aspartic acid, the two benzyl esters of 2-tryptophyl-beta-tetrahydro carboline-3-formyl radical-L-glutamic acid.
2. method for preparing the described compound of Formula I of claim 1 comprises:
(1) tryptophan transfer is become the Boc-tryptophane;
(2) tryptophan transfer is become beta-tetrahydro carboline-3-carboxylic acid;
(3) change beta-tetrahydro carboline-3-carboxylic acid into beta-tetrahydro carboline-3-benzyl carboxylate;
(4) change amino acid into amino-acid benzyl ester;
(5) with Boc-tryptophane and beta-tetrahydro carboline-3-benzyl carboxylate condensation prepared 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-benzyl carboxylate;
(6) 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-benzyl carboxylate hydrogenolysis is prepared 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-carboxylic acid;
(7) with 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-carboxylic acid and prepared amino-acid benzyl ester condensation prepared 2-(Boc-the tryptophyl)-beta-tetrahydro carboline-3-formyl amino acid formyl amino acid benzyl ester of step (4);
(8) 2-(Boc-tryptophyl)-beta-tetrahydro carboline-3-formyl amino acid formyl amino acid benzyl ester is sloughed protecting group Boc, promptly.
3. a pharmaceutical composition for the treatment of tumour is gone up the described compound of Formula I of claim 1 and the acceptable accessories of significant quantity and is formed by treatment.
4. the described compound of claim 1 is in the purposes of preparation in the antitumor drug.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101144033A CN101597289B (en) | 2008-06-02 | 2008-06-02 | 2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101144033A CN101597289B (en) | 2008-06-02 | 2008-06-02 | 2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101597289A CN101597289A (en) | 2009-12-09 |
CN101597289B true CN101597289B (en) | 2011-09-21 |
Family
ID=41418908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101144033A Expired - Fee Related CN101597289B (en) | 2008-06-02 | 2008-06-02 | 2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101597289B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102241604B (en) * | 2010-05-12 | 2013-11-06 | 首都医科大学 | Amino acid modified curcumin, synthesis method thereof, and application thereof |
CN102250202B (en) * | 2010-05-19 | 2013-08-28 | 首都医科大学 | 1-paranitrophenyl-beta-carboline-3-formyl amine acid carbamates and synthesis method and use thereof |
CN109912587B (en) * | 2017-12-12 | 2020-07-28 | 首都医科大学 | Side chain protection amido n-hexanoyl carboline benzyl carboxylate, preparation, activity and application thereof |
CN109912588B (en) * | 2017-12-12 | 2020-06-19 | 首都医科大学 | 6-amino amido n-hexanoyl carboline benzyl carboxylate, preparation, activity and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217332A (en) * | 1997-11-14 | 1999-05-26 | 阿迪尔公司 | Metal protease inhibitor, preparation method therefor and medicinal composition containing same |
WO2005117868A1 (en) * | 2004-05-26 | 2005-12-15 | Bristol-Myers Squibb Company | Tetrahydrocarboline antiviral agents |
CN1910183A (en) * | 2004-01-23 | 2007-02-07 | 希龙公司 | Tetrahydrocarboline compounds as anticancer agents |
-
2008
- 2008-06-02 CN CN2008101144033A patent/CN101597289B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217332A (en) * | 1997-11-14 | 1999-05-26 | 阿迪尔公司 | Metal protease inhibitor, preparation method therefor and medicinal composition containing same |
CN1910183A (en) * | 2004-01-23 | 2007-02-07 | 希龙公司 | Tetrahydrocarboline compounds as anticancer agents |
WO2005117868A1 (en) * | 2004-05-26 | 2005-12-15 | Bristol-Myers Squibb Company | Tetrahydrocarboline antiviral agents |
Non-Patent Citations (3)
Title |
---|
Medicinal Chemistry》.2006,第14卷4761-4774. * |
Ming Zhao et al.Synthesis of new class dipeptide analogueswith improved permeability and antithrombotic activity.《Bioorganic & Medicinal Chemistry》.2006,第14卷4761-4774. |
Ming Zhao et al.Synthesis of new class dipeptide analogueswith improved permeability and antithrombotic activity.《Bioorganic & * |
Also Published As
Publication number | Publication date |
---|---|
CN101597289A (en) | 2009-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101906102B (en) | Beta-carboline alkaloid derivative, preparation method and application thereof | |
CN102241604B (en) | Amino acid modified curcumin, synthesis method thereof, and application thereof | |
CN103159828B (en) | 1-(4-hydroxy-3-methoxycarbonyl)-beta-carboline-3-formyl tryptophyl amino acid benzyl ester, and synthesis and application thereof | |
CN103450329B (en) | 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters and their synthesis, anti-tumor activity and use | |
CN106349148A (en) | Novel indoles compound having anti-tumor metastasis activity and anti-inflammatory activity, as well as synthesis and application of novel indoles compound | |
CN103889439A (en) | Crystal forms of a HCV protease inhibitor | |
CN103450340B (en) | The antineoplastic oligopeptide that heterocyclic carboxylic acid is modified, its synthesis, antitumor action and application | |
CN102675416B (en) | Beta-carboline derivatives, and preparation method and application thereof | |
CN102250203B (en) | Beta-carboline aminoacid benzyl ester, preparation method and application thereof | |
CN106632383B (en) | Curcuma zedoary 01 derivatives and preparation method thereof and the application in antitumor drug | |
CN101597289B (en) | 2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester and preparation method and application thereof | |
CN101597291B (en) | 2-aminoacyl tryptophyl-Beta-tetrahydric carboline-3-carboxylic acid carbobenzoxy as well as preparation method and application thereof | |
CN102295618B (en) | Nitric oxide donor tamibarotene derivatives and their preparation method and use | |
CN102898502B (en) | Coumarin derivative, and its preparation method and application | |
CN103509011B (en) | 1-(4-hydroxyl-3-formamido group acidic group-phenyl)-β-carboline, preparation, anti-inflammatory and anti-tumor activity and application | |
CN105367601A (en) | Curcumin derivative and preparation method therefor | |
CN101597290B (en) | Beta-carboline-3-formyl tryptophyl amine acid carbamate as well as preparation method and application thereof | |
CN101497611A (en) | N-(3-carboxyl-9-benzyl carboline-1-yl) ethyl amino acid, as well as synthesizing method and use thereof | |
CN103965458A (en) | Polyethylene glycol-amino acid oligopeptide-dasatinib conjugate and pharmaceutical composition thereof | |
CN103450332B (en) | The tripeptide benzyl ester that vinylbenzene-β-carboline is modified, its preparation, anti-tumor activity and application | |
CN104926804B (en) | One kind has compound, the preparation method and use of antitumor action | |
CN107629056B (en) | Benzimidazole quinazoline salicyloyl amino acid benzyl ester, preparation thereof, anti-tumor activity thereof and application thereof | |
CN103450198B (en) | Imidazo pyrido imidazole-3-substituted benzyl acetates, and synthesis, antineoplastic activities and application thereof | |
CN102702297B (en) | Preparation method of cholic acid-naphthalimide compound | |
CN109134595B (en) | Theanyl amino acid benzyl ester modified curcumin, and synthesis, activity and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110921 Termination date: 20140602 |